Title |
Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine
|
---|---|
Published in |
Frontiers in oncology, September 2014
|
DOI | 10.3389/fonc.2014.00258 |
Pubmed ID | |
Authors |
Donna M. Graham, Natasha B. Leighl |
Abstract |
A paradigm-shift in the management of non-small cell lung cancer (NSCLC) has resulted in many new therapies becoming available for patients with advanced disease. Stratification of treatment by histologic and molecular subtype is recommended to obtain the greatest clinical benefit for patients while minimizing adverse effects of treatment. However, these advances in diagnosis and treatment of NSCLC have come at a financial cost. This review highlights the economic impact of screening for molecular abnormalities and targeted treatment for advanced NSCLC. Major determinants of cost are drug acquisition and molecular testing. As technologies advance, molecular testing costs may reduce. However, we must collaborate with payers and manufacturers to ensure that high drug costs do not limit patient accessibility to potentially beneficial treatment. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 31 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 19% |
Student > Bachelor | 4 | 13% |
Student > Postgraduate | 4 | 13% |
Researcher | 3 | 10% |
Professor > Associate Professor | 3 | 10% |
Other | 7 | 23% |
Unknown | 4 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 39% |
Agricultural and Biological Sciences | 4 | 13% |
Economics, Econometrics and Finance | 4 | 13% |
Immunology and Microbiology | 2 | 6% |
Nursing and Health Professions | 1 | 3% |
Other | 4 | 13% |
Unknown | 4 | 13% |